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ABSTRACT
Candidates from Chinese herbal Medicine might be preferable in drug discovery as 
the abundant experiences of traditional use usually hint the clinical efficacy. In this study, 
we screened the anti-tumour effect of several commonly used Chinese herbal Medicines 
on human hepatocellular carcinoma cells (HCC). We identified that Salvia chinensia Benth. 
(Shijianchuan in Chinese, SJC) exhibited prominent in vitro inhibition of HCC cells and 
suppressed the orthotopic growth of HCC in the liver of mice and repressed the lung 
metastasis of tumour cells. Using a pathway-specific PCR array and Gene Ontology analysis, 
we identified that Wnt/β-catenin pathway was associated with the suppressive effect of 
SJC on HCC cell proliferation and cell cycle progression. SJC repressed transcription activity 
of Wnt/β-catenin pathway and reduced expression of β-catenin in GSK-3β-independent 
but promoter-specific transcription inhibition mechanism. The suppressive effect of SJC 
on β-catenin expression and its transcription activity was associated with Wilms’ tumor 1 
(WT1) protein. WT1 was overexpressed in HCC tissues, and was negatively correlated to 
the overall survival of HCC patients. WT1 promoted proliferation and invasion of HCC cells, 
as well as β-catenin-dependent transcription activation of Wnt products, while knockdown 
of WT1 had the opposite effect. Docking experiment revealed that protocatechualdehyde 
(PCA) might be the active component of the herb. PCA suppressed transcription activity of 
Wnt/β-catenin pathway in WT1-dependent manner. Our study sheds light on the potential 
of PCA from commonly used anti-cancer Chinese herbal Medicine SJC as a lead compound 
targeting WT1 in the discovery of anti-HCC drugs.
INTRODUCTION
Hepatocellular carcinoma is one of the most 
malignant human cancers that results in increasing annual 
cancer death, ranking the second highest mortality rate all 
over the world [1]. Although a few of HCC patients may 
be suitable for surgical resection and liver transplantation 
which gain satisfactory therapeutic outcome [2], a large 
number of patients suffering unresectable HCC can 
only be given treatments such as transcatheter arterial 
chemoembolization (TACE) and sorafenib, whose 
outcome may be less satisfactory [3]. A recent study 
analysing multiple levels of comprehensive genomic 
characterization of HCC suggested Wnt signalling is 
one of the potential targets of next generation treatments 
[4]. Activation of Wnt signalling is involved in various 
processes of HCC development, and β-catenin, which 
is encoded by human CTNNB1 gene, plays a central 
role in mediating the hyper-activation of Wnt signalling 
during hepatic carcinogenesis and cancer progression [5]. 
Overexpression of β-catenin was found in HCC cases [6], 
and it is believed that ablation of epigenetic and genetic 
control of this gene is the leading cause of overexpression 
[7]. Approved target-specific therapies on Wnt/β-catenin 
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signalling are yet not available, however, some studies 
have shown that inhibition of Wnt/β-catenin can improve 
the sensitivity of HCC in response to sorafenib [8, 9], 
as Wnt/β-catenin signalling was found to mediate the 
mechanism of resistance of HCC cells towards sorafenib 
treatment [10, 11].
Some of the Chinese herbal Medicines have been 
widely reported for their inhibitory effect on HCC at 
pre-clinical and clinical levels [12, 13]. It has been 
summarized by other’s and our labs that a list of Chinese 
herbal Medicines is commonly used in the clinical 
treatment of HCC by physicians, including some of which 
were rarely studied in scientific extent [13-16]. Although 
clinical experience on the use of these Chinese herbal 
Medicines might hint its therapeutic potential, scientific 
evidences underlying its anti-tumour activity was scanty. 
On the other hand, identification of novel anti-tumour 
lead compounds from herbal Medicine, as successful as 
the cases of paclitaxel and camptothecin [17], requires 
both understandings on the disease targets and chemical 
compositions of the complicated herbal extracts. The 
integration of experimental validation with computational 
data mining is a helpful approach to overcome the 
technology barriers in identifying target-specific and 
active molecules from Chinese herbal Medicine. Recently, 
a study has shown the powerfulness of combining 
molecular docking with experimental verification in 
fishing the active ingredients of Chinese Herbal Remedy 
Free and Easy Wanderer in treating mental disorder [18]. 
The successful application of this study pattern suggested 
its potential application in efficient drug discovery from 
Chinese herbal Medicine [19].
In this study, we first of all screened several 
rarely studied Chinese herbal Medicines that have 
been extensively used in clinical treatment of HCC 
by Chinese Medicine practitioners. We identified that 
Salvia chinensia Benth. (Shijianchuan in Chinese, SJC) 
was the most prominent suppressor of HCC growth. We 
systemically evaluated the in vitro and in vivo anti-HCC 
activity of SJC, and identified by disease-specific array 
that WT1-associated Wnt/β-catenin was involved in the 
pharmacological action of SJC. As a novel oncogene in 
HCC, the clinical significance and biological function of 
WT1 was determined in this study. In addition, prediction 
and validation of biologically active ingredient of SJC 
was performed using computational molecular docking 
combined with bioassay validation.
RESULTS
Aqueous extract of Salvia chinensia Benth. 
exhibited potent inhibition on in vitro 
proliferation and viability of HCC cells
A plenty of Chinese herbal Medicines are commonly 
prescribed to patients with HCC in the clinical practice 
of Chinese Medicine practitioners [13]. Some were 
extensively studied in the past decades, such as Coptis 
chinensis Franch. (Huanglian in Chinese), Oldenlandia 
diffusa (Willd.) Roxb (Baihua Sheshe Cao in Chinese), 
Sophora flavescens Ait. (Kushen in Chinese) and Radix 
ginseng (Renshen in Chinese). Here we selected eight 
less studied anti-HCC Chinese herbal Medicines to 
screen the in vitro cytotoxicity (Figure 1A). Aqueous 
extract of each individual herb was made and the in 
vitro cytotoxicity towards human HCC cells PLC/
PRF/5 and MHCC97L was measured by MTT assay. It 
was shown that among the eight herbs, Salvia chinensia 
Benth. (Shijianchuan in Chinese, SJC, chromatographic 
fingerprint at Supplementary Figure 1) exhibited the most 
potent inhibition on the viability of HCC cells (IC50 equal 
to 500, 250 and 200μg/mL at 24, 48 and 72 h-treatment in 
PLC/PRF/5 cells, and equal to 1000, 600 and 300μg/mL 
at 24, 48 and 72 h-treatment in MHCC97L cells, Figure 
1B&1C). Paris polyphylla (Qiye Yizhi Hua in Chinese, 
QYYZZ) and Smilax china L. (Baiqia in Chinese, BQ) 
possessed similar cytotoxicity with SJC at 24 to 48 h, 
while HCC cells quickly acquired adaptation which 
rendered resistance to longer treatment of QYYZZ and 
BQ. Inhibition of clony formation of both HCC cells by a 
12-day constitutive treatment with SJC further proved the 
long-term inhibitory effect of SJC extract on HCC cells 
without obvious resistance observed.
Oral administration of SJC extract suppressed 
in vivo proliferation and metastasis of HCC
To further examine the clinically relevant anti-
HCC effect of SJC, we established the orthotopic HCC 
implanted model in nude mice. Luciferase reporter was 
transfected into MHCC97L, the cell line that was then 
used to generate a small cube of solid tumour being 
implanted to the left lobe of receiving mice. Body 
weight measurement revealed that oral treatment of SJC 
extract (100 mg/kg/day) had minimal effect on body 
weight, indicating no observational toxicity of the herb 
(Figure 2A). in vivo imaging showed that SJC treatment 
repressed the orthotopic tumour growth of HCC. While 
mice receiving vehicle treatment gained enlarging hepatic 
tumour, the increase in tumour size and reporter signal 
intensity in SJC-treated mice was not potent (Figure 2B). 
This was complying with the end-point observation, which 
showed that mice with vehicle treatment had a larger 
liver tumour than mice treated with SJC (Figure 2C). 
This proved the in vivo inhibitory effect of SJC on HCC 
proliferation and growth. Furthermore, as lung metastasis 
was one of the indicators of HCC aggressiveness [20], we 
measured if SJC treatment could block the extrahepatic 
spread of HCC cells in mice. Dissected lung from mice 
with vehicle treatment exhibited strong luciferase signal, 
indicating a severe lung metastasis of HCC cells; weak 
to none signal could be detected in lung from mice with 
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SJC treatment, suggesting that the lung metastasis was 
completely blocked. Our findings suggested that SJC 
suppressed in vivo proliferation and distant metastasis of 
HCC without exhibiting obvious toxicity.
SJC intervention might impede cell proliferation 
and cell cycle progression and block canonical 
Wnt pathway
To make a global understanding on the 
pharmacological effect of SJC, we introduced HCC-
specific pathway PCR array. A series of genes were 
regulated by SJC in HCC cells, nine of which were 
down-regulated while six were induced (Figure 3A, 
Supplementary Table 2). Enrichment on the biological 
process that the regulated genes were involved in 
showed that SJC could interfere cellular process related 
to DNA transcription (GO:0045893), cell proliferation 
(GO:0008285) and cell cycle progression (GO:0007050), 
all of which might contribute to the rapid growth of liver 
tumour (Figure 3B, Supplementary Table 3). Interestingly, 
it was noticed that the action of SJC might also involve 
Figure 1: SJC suppressed hepatocellular carcinoma cells in vitro. (A) representative images of eight commonly used Chinese 
herbal Medicines in the clinical treatment of HCC; (B) cytotoxicity of aqueous extract of Chinese herbal Medicines on human HCC cell 
line MHCC97L; (C) cytotoxicity of aqueous extract of aforementioned Chinese herbal Medicine on human HCC cell line PLC/PRF/5; (D) 
SJC suppressed growth of MHCC97L and PLC/PRF/5 cells, as indicated by colony formation assay.
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regulation on the canonical Wnt pathway (GO:0060070). 
We further analysed the involving genes into String 
database to figure out the potential interactive network 
underlying SJC’s pharmacological action. The protein 
network constructed by Cytoscape further confirmed 
that a series of members of Wnt/β-catenin pathway were 
involved (Figure 3C), which covered from the upstream 
co-regulator APC, executor β-catenin and effector c-fos. In 
addition, genes in the regulation of cell cycle might be also 
involved. To validate the prediction biological process, 
we analysed the cell cycle progression and proliferation 
of HCC cells upon SJC treatment. PI staining of cellular 
DNA revealed that SJC could halt the cell cycle at G0/G1 
stage (Figure 3D). BrdU incorporation assay showed that 
the proliferation rate of HCC cells was slowed down by 
SJC treatment (Figure 3E). These findings suggested that 
the pharmacological action of SJC was associated with the 
regulation of cell proliferation and cell cycle progression 
via Wnt/β-catenin pathway.
SJC suppressed Wnt/β-catenin pathway in WT1-
dependent and GSK3β-independent manner
To further understand the action and action of 
mechanism underlying regulation of Wnt/β-catenin 
pathways by SJC, we exposed HCC cells with SJC in the 
presence or absence of Wnt3a, a stimulator of canonical 
Wnt pathway. Treatment of SJC could significantly 
suppress the expression of Wnt pathway product genes 
(Figure 4A). The inhibitory effect of SJC on transcription 
of Wnt pathway products could sustain during the 
treatment, and re-exposure of Wnt3a for 6 h after SJC 
treatment cannot recover the transcription activity of 
Wnt signalling. Immnoblotting analysis showed that SJC 
treatment substantially suppressed expression of β-catenin, 
whose expression and protein stabilization are required 
for the Wnt activation and subsequent gene transcription 
[21]. SJC had minimal effect on the phosphorylation of 
GSK3β, the internal inhibitor of β-catenin by mediating 
its phosphorylated degradation [22] (Figure 4B). This 
observation together with the finding that the mRNA 
transcripts of β-catenin were reduced in SJC-treated HCC 
cells (Figure 4A) indicated a posttranslational regulation-
independent mechanism may be involved. Suppression 
of β-catenin expression by SJC cannot be attenuated by 
GSK3β inhibitor LiCl, further proving that the inhibitory 
effect of SJC on β-catenin expression was independent 
to GSK3β (Figure 4C). Notably, the constructed protein 
network underlying pharmacological action of SJC and 
Immunoblotting analysis revealed the involvement of 
Wilms’ tumor protein (WT1) in the regulatory network 
of Wnt/β-catenin pathway. To examine if WT1 was 
involved in the regulation of β-catenin by SJC, we re-
expressed WT1 in SJC-treated HCC cells. Recovery 
of WT1 expression was confirmed by qPCR, and WT1 
re-expression could restore the mRNA transcription of 
Wnt pathway products as well as β-catenin expression 
(Figure 4D). Luciferase reporter assay also revealed that 
Figure 2: SJC exhibited anti-tumour effect in orthotopic HCC implantation model. (A) shows oral administration of SJC 
had minimal effect on the body weight of athymic nude mice; (B) shows SJC can regress orthotopic growth of implanted HCC, as indicated 
by luciferase reporter-dependent live animal imaging; reduced signal intensity in SJC-treated mice reveals smaller tumour size; (C) shows 
representative images of HCC in the liver of mice; (D) shows that SJC suppressed distant metastasis of HCC towards lung tissue, as 
indicated by bare-to-none luciferase signal in the lungs of SJC-treated mice.
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suppression of β-catenin transcription by SJC was partially 
recovered by re-expression of WT1 in HCC cells (Figure 
4E). Our findings suggested that SJC inhibited Wnt/β-
catenin pathway in WT1-dependent manner.
WT1 was overexpressed in HCC and facilitated 
proliferation and invasion of HCC cells
Although some previous studies have shown 
that WT1 expression in HCC was associated with its 
poor prognosis [23], the clinical-relevant biological 
function of WT1 on HCC has not been fully unveiled. 
To further evaluate the potential of WT1 as a possible 
drug target in HCC treatment, we analysed the clinical 
significance of WT1 expression in HCC by extracting 
GEO database GSE14323 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE14323). WT1 was 
significantly overexpressed in HCC tissue in compared 
with non-tumour liver (Figure 5A). KM plot analysis on 
survival data of HCC patients showed that patients with 
higher expression of WT1 in tumour (greater than 1.3 
FPKM, data from transcriptomic sequencing of TGCA 
database) exhibited lower median survival than those with 
lower expression of WT1 (less than 1.3 FPKM; Figure 
5B, p=0.0356). These may suggest high expression of 
WT1 in HCC would link to poor survival outcome. To 
further understand the biological function of WT1, we 
overexpressed and knock-downed WT1 in HCC cells. 
Expression of Wnt pathway products was regulated 
upon the genetic modification of WT1 in HCC cells. 
Overexpression of WT1 could increase transcription of 
Wnt pathway products while silence of WT1 suppressed 
transcription activation upon Wnt3a stimulation (Figure 
5C). To examine if the activation of Wnt pathway by 
WT1 was dependent on β-catenin, we interfered β-catenin 
in WT1-overexpressing HCC cells. Knockdown of 
β-catenin in WT1-overexpressing HCC cells repressed 
expression of Wnt pathway products, which suggested 
Figure 3: SJC caused multiple changes of gene expression that are involved in cell cycle and proliferation regulation. 
(A) heatmap of analysis on the PCR pathway array. SJC treatments induced expression change of a series of genes in MHCC97L; (B) GO 
analaysis on the genes with differential expression. It was found that Wnt/β-catenin pathway was enriched with most significant p-value; 
(C) genes in Wnt/β-catenin pathway that was regulated by SJC treatment; (D) SJC led to G0/G1 cell cycle arrest in HCC cells; (E) SJC 
treatment inhibited population of HCC cells with rapid proliferation (S phase).
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the necessary role of β-catenin in mediating WT1-
induced Wnt activation (Figure 5D). Functional assays 
revealed that overexpression of WT1 could promote the 
proliferation and invasion of HCC cells, while knockdown 
of WT1 impeded HCC cells (Figure 5E&5F). These 
findings suggested high expression of WT1 promoted 
HCC proliferation and invasion with involvement of Wnt 
activation.
Protocatechualdehyde (PCA) from SJC was 
responsible for the inhibition of WT1-associated 
Wnt activation
To further understand the molecular basis of the 
anti-HCC action, we tried to explore the possible active 
components of SJC with combination of computational 
and experimental approaches. First, we searched for 
chemical ingredients SJC on Traditional Chinese 
Medicine Systems Pharmacology Database (TCMSP, 
http://lsp.nwsuaf.edu.cn/). Compounds with favourable 
pharmacokinetic properties (OB ≥ 33% and Caco2 ≥ 0.4 
cm/s) were selected. Five compounds (PCA, vanillin, 
syringaldehyde, ferulaldehyde and β-sitosterol) were 
shortlisted. As β-sitosterol has wide distribution in a lot 
of natural plants and may not be a specific component 
of SJC, only four phenolic compounds were performed 
molecular docking analysis with particular structure 
of several proteins identified in the regulatory network 
of Figure 3B. Among the Wnt proteins, c-fos exhibited 
no interaction with the input compounds, while APC, 
Figure 4: SJC suppressed Wnt/β-catenin pathway activity via regulating WT1-associated β-catenin transcription. (A) 
SJC suppressed transcription of Wnt/β-catenin products in HCC cells, indicating repression of Wnt/β-catenin pathway activity by SJC; (B) 
SJC suppressed expression of β-catenin without altering activity of GSK3β; (C) inhibition of GSK3β by LiCl cannot attenuate inhibition of 
Wnt/β-catenin pathway activity by SJC; (D) overexpression of WT1 restored expression of β-catenin as well as the transcription activity of 
Wnt pathway; (E) SJC possessed promoter-specific transcription inhibition mechanism on β-catenin expression.
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β-catenin and WT1 had less binding capacity with anillin, 
syringaldehyde and ferulaldehyde (Figure 6A). Using 
5.22 as a threshold of active binding score, only PCA was 
qualified to actively interact with the selected proteins, 
among which WT1 exhibited the highest binding potency 
with PCA (Figure 6B), and three residues of WT1, Arg44, 
Trp60 and Pro47 formed a pocket for the binding of PCA 
(Figure 6C). Reduced expression of Wnt pathway products 
upon PCA treatment was experimentally observed (Figure 
6D), and overexpression of WT1 attenuated this inhibitory 
effect (Figure 6E), confirming that the inhibitory effect 
of PCA on Wnt activation was associated with WT1 
expression in HCC cells.
DISCUSSION
The inhibitory effect of SJC has ever reported by a 
previous study with some individual signalling pathways 
were examined [24]. A global screening may be necessary 
for identifying the true target of SJC in treating HCC. By 
applying PCR pathway array, we tried to elaborate the 
pharmacological action of Chinese herbal Medicine in the 
throughout approach. Although SJC extract may contain a 
series of compounds in different structure and bioactivity, 
the overall outcome of regulation on cellular signalling 
by such a complicated mixture shall be identifiable by 
means of detection of changes on global gene profile 
[25]. Assays may differ in terms of throughput level, but 
outcome of analyses shall be identical. In our study, by 
visiting the differential gene expression, we identified that 
Wnt pathway was majorly involved in the action of SJC 
on HCC cells.
The inhibitory effect of PCA on human tumour cells 
was reported in a few previous studies. It was particularly 
noticed by Jeong and colleague that PCA can potently 
inhibit growth of colorectal cancer cells with suppression 
of HDAC2 and Cyclin D1 expression. To be sepcific, 
PCA suppressed Cyclin D1 at transcriptional level, as 
PCA reduced both Cyclin D1 promoter activity and 
mRNA expression in colorectal cancer cells [26]. Further 
studies supported the notion that PCA-induced Cyclin 
D1 inhibition may subsequently cause cell cycle arrest 
and apoptosis of various human cancer cells [27, 28]. 
Noticeably, a recent study revealed that PCA-suppressed 
Cyclin D1 can be dependent on Wnt/β-catenin pathway. 
The effect of PCA on the pathway can be partially 
dependent to the protein stability of β-catenin, but more 
importantly, to nuclear translocation of NF-κB, suggesting 
a NF-κB-associated transcriptional inhibition mechanism 
of β-catenin might be involved and NF-κB may play as 
a transcription repressor of β-catenin [29]. In our study 
we found that WT1 can positively regulate Wnt pathway 
activity through promoting β-catenin transcription. While 
previous study has demonstrated that NF-κB did not 
regulate WT1 expression [30], it may be postulated that 
WT1 and NF-κB may have interaction with β-catenin 
promoter. As WT1 and NF-κB was found to physically 
interact with each other in mammalian cells [31], the 
Figure 5: WT1-promoted HCC progression was associated with Wnt/β-catenin pathway. (A) mining of GSE14323 dataset 
revealed that WT1 was overexpressed in HCC tissue compared with non-tumour liver; (B) high expression of WT1 was associated with 
poor survival in HCC patients. Data was mined from TGCA database and KM plot was created by grouping survival data of patients with 
WT1 mRNA expression higher than 1.3 from those lower than 1.3; (C) WT1 regulated activity of Wnt/β-catenin pathway; HCC cells 
overexpressing WT1 exhibited increased production of Wnt/β-catenin targets, while knockdown of WT1 expression repressed transcription 
of Wnt/β-catenin products; (D) knockdown of β-catenin abrogated WT1-induced Wnt/β-catenin pathway; (E) overexpression of WT1 
promoted HCC cell invasion while WT1 knockdown blocked invasion of HCC cells. Expression of WT1 was shown in c; (F) overexpression 
promotes HCC cell proliferation while WT1 knockdown retarded its growth. Expression of WT1 was shown in c.
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WT1-mediated β-catenin may be probably through 
recruiting NF-κB to form protein complex and therefore 
releasing β-catenin promoter from NF-κB-mediated 
suppression on transcription initiation.
We observed that the effect of SJC on Wnt/β-catenin 
signalling was associated with WT1 in HCC cells. An 
integrated genome-wide screening have identified that 
the activity of Wnt/β-catenin signalling is associated 
with WT1 expression [32]. An earlier study has mapped 
the promoter region of Wnt-4, ligand of Wnt pathway. It 
was found that though Wnt-4 promoter presents several 
binding site of WT1, the regulation of WT1 on Wnt-4 
expression may be indirect [33]. However, Schittenhelm 
and colleague reported that there was no evidence to show 
Figure 6: PCA may be the active ingredient of SJC in suppressing HCC. (A) shows the binding of potential of compounds 
in SJC with possible molecular targets. Only PCA showed active binding to the proteins in which WT1 exhibited higher binding score 
with PCA; (B) shows the 3D image of binding profile between WT1 protein and PCA; (C) shows residues of WT1 protein that can 
interact with PCA; (D) PCA suppressed transcription of Wnt/β-catenin products in HCC cells; (E) overexpression of WT1 restored the 
transcription activity of Wnt/β-catenin pathway in PCA-treated cells; (F) the schematic representative of regulatory mechanism underlying 
WT1-mediated inhibition of HCC by SJC.
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that WT1 was involved in the regulation of non-canonical 
Wnt pathway which was mediated by Wnt-4/β-catenin 
[34]. Knockout of WT1 reduced expression of canonical 
Wnt pathway elements LEF1 and CTNNB1, suggestive 
of diminished canonical Wnt signalling [35]. It was also 
found that in testis cells, knockdown of WT1 can reduce 
expression of Lef1 and Ptch1, indicating suppression of 
Wnt signalling [36]. These observations in accordance 
with our findings may reveal that WT1 can regulate 
the canonical instead of non-canonical pathway of Wnt 
signalling. Furthermore, in our study, with luciferase 
reporter assay we found the transcriptional regulation of 
SJC onβ-catenin expression, however, we cannot directly 
conclude that WT1 serves as transcription factor that 
binds to CTNNB1 promoter region. Indeed, a recent study 
revealed that WT1 can repress EZH2-mediated epigenetic 
silencing of CTNNB1 gene, and therefore promote 
β-catenin expression [37]. The transcriptional regulation of 
WT1 on β-catenin may thus be indirect and is dependent 
to the presence of other determinant factors. This may 
also explain the observations that in some circumstances, 
WT1 may serve as a repressor of β-catenin [38-41]. The 
exact mechanism of WT1-regulated Wnt/β-catenin activity 
needs further investigation.
In this study, we identified the anti-tumour activity 
of a clinically used Chinese herbal Medicine Salvia 
chinensia Benth. (Shijianchuan in Chinese) in HCC. 
We screened and identified that SJC was one of most 
prominent herbs that possessed inhibition on HCC. SJC 
exhibited cytotoxicity in HCC cells, and suppressed 
the in vitro proliferation and cell cycle progression. In 
mice with orthotopic implanted HCC, oral treatment 
of SJC reduced tumour growth and lung metastasis. 
Disease-specific PCR array and GO analysis showed 
that Wnt/β-catenin was associated with the inhibitory 
effect of SJC, and WT1 might be the up-stream molecule 
that regulated Wnt/β-catenin activity. Treatment of SJC 
suppressed Wnt/β-catenin activity via repressing β-catenin 
transcription in HCC cells, which was independent 
to GSK-3β pathway but could be attenuated by WT1 
overexpression. As a novel identified oncogene, WT1 
was found overexpressed in human HCC compared with 
non-tumour liver, and its high expression correlates with 
low overall survival. Overexpression of WT1 promoted 
proliferation and invasion of HCC cells, and evoked 
Wnt/β-catenin signalling in β-catenin-dependent manner. 
Protocatechualdehyde was predicted to be the possible 
active ingredient in SJC by computational annotation 
and molecular docking. Suppression of Wnt/β-catenin 
signalling by protocatechualdehyde was attenuated by 
WT1 overexpression. Our study suggested that WT1-
regualted Wnt/β-catenin signalling may be a potential 
target of HCC treatment, and SJC and its active ingredient 
protocatechualdehyde may be possible for development of 
new treatment targeting WT1.
MATERIALS AND METHODS
Herbal extract preparation
Dried herbs of eight Chinese herbal Medicines, 
including Achyranthes bidentata Bl. (Niuxi in Chinese, 
NX), Salvia chinensia Benth. (Shijianchuan in Chinese, 
SJC), Fruit of Fiverleaf Akebia (Bayuezha in Chinese, 
BYZ), Portulaca Grandiflora (Banzhilian in Chinese, 
BZL), Solanum nigrum (Longkui in Chinese, LK), 
Radix Trichosanthis (Tianhuafen in Chinese, THF), Paris 
polyphylla (Qiye Yizhi Hua in Chinese, QYYZH) and 
Smilax china L. (Baqia in Chinese, BQ), were collected 
from the clinical centre of School of Chinese Medicine, 
The University of Hong Kong. All the herbs were 
authenticated by Dr. Feng Yibin. Species of individual 
herb were kept and voucher numbers were given. To 
obtain the aqueous extracts of Chinese herbal Medicines, 
minced herb was boiled twice with 10 times of water for 
2 h, follow by freeze-dry of the extracts. The dry powder 
was kept in -20°C and reconstituted in appropriate vehicle 
before use. Doses used in this study were presented in 
equal weight of raw herb per millilitre of vehicle.
Cell lines and cell culture
Human hepatocellular carcinoma cell line PLC/
PRF/5 was obtained from ATCC (USA). MHCC97L cells 
expressing luciferase reporter gene were kindly gifted by 
Prof. Man Kwan in Department of Surgery, The University 
of Hong Kong. All cells were maintained by Dulbecco’s 
Modified Eagle’s Medium (DMEM, high glucose) 
supplemented with 10% Fetal Bovine Serum (FBS) and 
1% Penicillin/Streptomycin in humidified condition with 
5% CO2 at 37°C.
siRNA, plasmid and transfection
siRNA against human β-catenin was purchased from 
Santa Cruz. pAd/WT1-IRES-nAmCyan was a gift from 
Edward McCabe (Addgene plasmid # 29756). shRNA 
against WT1 and β-catenin promoter reporter were from 
Genecopoeia (USA). Transfection was conducted with 
FuGene Transfection reagent (Promega, USA). In brief, 
corresponding nucleotide was mixed with FuGene reagent 
in serum free medium (1:2, w/v) followed by 15 min 
incubation at room temperature. The mixture was then 
added to the cells and incubated for 24 to 72 h. Treatment 
was applied during the incubation if necessary.
Orthotopic HCC implantation in athymic nude 
mice
Protocol of animal experiment has been approved 
by the Committee on the Use of Live Animals in Teaching 
and Research (CULATR) of the University of Hong 
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Kong (Ref: 3776-15). Orthotopic HCC implantation was 
performed on 6-week nude mice with surgical procedure 
reported by our previous study [42]. In brief, solid tumour 
was formed by subcutaneously injecting luciferase-tagged 
MHCC97L cells into the right flank of athymic nude 
mice. Small cube of tumour was then cut and implanted 
into the left lobe of liver of receiving mice. 7 days after 
implantation, mice were given SJC treatment (100 mg/
kg/day) via oral gavage for 5 weeks. Growth of hepatic 
tumour was monitored weekly under IVIS live animal 
imager. At the end of study, mice were sacrificed by 
overdose pentobarbital (200 mg/kg) and liver and lung 
were dissected out for imaging.
RNA extract, PCR array and real-time PCR
Total RNA was extracted using RNeasy mini kit 
(Qiagen, Germany) under manufacturer’s instruction. 
First strand cDNA was prepared with RT2 First Strand Kit 
(Qiagen, Germany). For PCR array, the pre-coated Liver 
Cancer RT2 Profiler kit (PAHS-133Z, Qiagen, Germany) 
was used; for real-time PCR, cDNA was amplified in 
SYBR Green I reagent (Takara, Japan) with specific 
primer sets (Supplementary Table 1) for particular genes. 
All the assays were performed on LC480 platform (Roche, 
USA).
Flow cytometry
For analysis of cell cycle, synchronized cells were 
treated with SJC and fixed in 70% Ethanol, followed 
by propidium iodide (PI, 50 μg/mL, Sigma-aldrich, 
USA) staining in dark for 40 min. For analysis of cell 
proliferation, SJC-treated cells were incubated with 
BrdU reagents for 1 hr. Staining was performed with 
FITC BrdU Flow Kit (BD Bioscience, USA) according 
to manufacturer’s instruction. Cell cycle and proliferation 
were then analysed on Canto II flow cytometer (BD 
Bioscience, USA).
Luciferase reporter assay
Cells transfected with GLuc-ON containing promoter 
region of human β-catenin (Genecopeia, USA) were treated 
with SJC for 48 h. Cells were then lysed and the firefly 
luciferase activity was detected. The lysate was detected by 
adding 150 μg/mL luciferin (Promega, USA) as substrate 
and measuring the signal intensity on IVIS imager.
Computational modelling
List of ingredients in SJC was extracted from on 
Traditional Chinese Medicine Systems Pharmacology 
Database (TCMSP, http://lsp.nwsuaf.edu.cn/). Only 
compounds which meet the criteria of oral availability 
(OB) ≥ 33% and predicted permeability on Caco2 cells 
(Caco2) ≥ 0.4 cm/s were shortlisted. Structure of the 
shortlisted compounds as well as protein PDB IDs were 
input into the on-line docking software systemDocks 
(http://systemsdock.unit.oist.jp/iddp/home/index/). 
Binding portfolio of compound-protein pairs was shown 
when the predicted active binding score was larger than 
default threshold (5.22 in the case).
Statistical analysis
Results were analysed using One-way ANOVA and 
expressed as mean ± SD.
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